Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
IMV
Biotech
Cancer biotech IMV hunts for a deal as its cash clock ticks down
Down to its last $21 million, IMV asked Stonegate to explore strategic alternatives amid concerns about its ability to continue as a going concern.
Nick Paul Taylor
Mar 16, 2023 8:28am
IMV drops 3rd of staff in refocus on lead oncology asset
Sep 15, 2022 9:45am
IMV's T-cell programming treatment keeps ovarian cancer at bay
Feb 25, 2020 11:08am